ReviewMolecular oncology2015
Harnessing adaptive natural killer cells in cancer immunotherapy.
Review in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.Genome medicine · 2020Trial
- Adaptive single-KIRJournal for immunotherapy of cancer · 2022Article
- Selective Expansion of NKG2C+ Adaptive NK Cells Using K562 Cells Expressing HLA-E.International journal of molecular sciences · 2022Article
- Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis.Disease markers · 2022Article
- NK cell upraise in the dark world of cancer stem cells.Cancer cell international · 2021Review
- Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia.Cellular & molecular immunology · 2021Article
- Prospects for NK Cell Therapy of Sarcoma.Cancers · 2020Review
- Deciphering Natural Killer Cell Homeostasis.Frontiers in immunology · 2020Review
- Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.Seminars in immunopathology · 2019Review
- Driving better and safer HER2-specific CARs for cancer therapy.Oncotarget · 2017Article
- Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.Immunogenetics · 2017Review
- Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.Clinical immunology (Orlando, Fla.) · 2017Article
- Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology.Immunology · 2017Review
- Lymphocytes in Placental Tissues: Immune Regulation and Translational Possibilities for Immunotherapy.Stem cells international · 2017Review
- Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies.Frontiers in immunology · 2017Article
- Harnessing adaptive natural killer cells in cancer immunotherapy.Molecular oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are innate lymphocytes with a refined ability to recognize transformed cells through a broad array of activating receptors in combination with stochastically expressed inhibitory receptors that recognize MHC-class I. Recent advances in NK cell biology have revealed a high degree of functional plasticity that can be attributed to dynamic cell-to-cell interactions in concert with transcriptional and epigenetic reprogramming. Here, we discuss how new insights into the adaptive behavior of NK cells pave the way for next generation cell therapy based on guided differentiation and selective expansion of particularly cytotoxic NK cell subsets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.